Business Context and Reporting Period
This Form 6-K filing by Check-Cap Ltd. (noted as Mbody AI Ltd. in metadata) covers the period of July 9, 2019. The registrant is a foreign private issuer based in Isfiya, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical study results and does not contain financial statements or quantitative financial data.
Material Changes
On July 9, 2019, Check-Cap Ltd. announced positive final results from a recently completed post-CE approval study. The study evaluated the clinical performance and safety of the company's C-Scan system.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section of the attached press release (Exhibit 99.1). No specific financial guidance, management commentary on future earnings, or detailed risk factors are provided within the body of this Form 6-K text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific clinical data points regarding the C-Scan system.
- Review the "Forward Looking Statements" incorporated by reference for potential risks and assumptions.
- Confirm the regulatory status of the C-Scan system following the post-CE approval study.
- Check subsequent filings for financial impact resulting from the clinical study results.